Suboxone Lawsuit [September 2026 Update] | Suboxone Tooth Decay Claims

The St. Mary’s County Board of County Commissioners voted to join a proposed multistate settlement with Indivior, the maker of Suboxone, as part of its September 15 consent agenda. 

Under the deal, Indivior agreed to pay $86 million over five years to resolve allegations that the company failed to monitor suspicious opioid orders and specifically targeted so-called dangerous prescribers, including operators of pill mills, through its promotional efforts.

New York, Illinois, Tennessee, Utah, and Virginia led negotiations on the settlement, which builds on a separate $600 million federal settlement Indivior reached back in 2020 over similar conduct. 

Under Maryland’s opioid settlement framework, money from deals like this flows into the state’s Opioid Restitution Fund, which distributes grants to local health departments, correctional facilities, and community organizations. 

The statewide fund held $100.6 million at the close of fiscal 2025, with roughly $282 million more expected through 2038.

This marks the latest in a string of opioid settlement actions St. Mary’s County has taken, following a $24 million regional settlement in 2023 and a separate $10 million allocation the same year, part of which went toward school-based initiatives. 

County officials haven’t yet said how they plan to allocate their share of the Indivior funds.

The Suboxone MDL recorded no change between August and September, holding steady at 1,827 cases.

The flat docket comes as the litigation advances through general and case-specific discovery, including work involving a pool of representative cases that could eventually inform bellwether trial selections.

With new filings largely stalled, the litigation remains focused on developing causation evidence and moving existing Suboxone film dental injury claims through coordinated pretrial proceedings.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

The Suboxone MDL decreased by 5 cases between July and August, declining from 1,832 to 1,827.

The slight decline comes as the litigation expands beyond Suboxone film to include claims involving Sublocade, with plaintiffs alleging the injectable formulation caused similar severe dental injuries.

The broader scope could influence discovery as attorneys develop evidence involving multiple buprenorphine products.

Although the docket remains relatively stable, the expanded claims continue to shape the direction of the Suboxone litigation.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

Five plaintiffs have filed a joint complaint against Indivior, joining the federal Suboxone tooth decay MDL.

The lawsuit alleges the company’s sublingual film formulation exposes users’ teeth to prolonged, direct contact with buprenorphine and naloxone, causing severe decay, cracking, and tooth loss.

Plaintiffs claim Indivior knew or should have known about a safer alternative formulation and delivery method but continued marketing the film version without adequate warnings about oral health risks.

Indivior now faces 17,911 federal Suboxone dental erosion lawsuits, according to a June 26 census report filed by the Plaintiffs’ Leadership Committee.

The litigation continues to move toward bellwether trials, with both sides required to select 15 representative cases by July 13, 2026.

The court plans to narrow those cases to four final bellwether selections by June 2027, with the first trial currently expected in March 2028.

The outcomes could help the parties assess how juries respond to claims that Indivior failed to adequately warn users about the risk of severe tooth decay, tooth loss, and other dental injuries linked to Suboxone film strips.

The Suboxone MDL decreased by 1 case between June and July, slipping from 1,833 to 1,832.

The slight change comes as the litigation broadened to include claims involving Sublocade injections, with plaintiffs alleging the extended-release formulation caused dental injuries similar to those alleged in the Suboxone lawsuits.

The expansion could increase the scope of the litigation as additional product-specific claims move into coordinated federal proceedings.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

Lawyers continue to review new claims involving severe dental injuries linked to buprenorphine-based opioid use disorder treatments.

According to the complaint, users developed severe tooth decay, tooth loss, and other oral health problems after receiving the injectable treatment.

While the litigation has primarily focused on Suboxone sublingual films, plaintiffs’ attorneys indicate that some former Sublocade users report similar dental complications and allege they were not adequately warned about the potential risks.

The development could broaden the scope of claims involving buprenorphine products as attorneys evaluate whether the dental injury allegations extend beyond Suboxone formulations.

Any expansion of claims involving Sublocade may increase the number of individuals seeking compensation for costly dental treatment and related injuries.

Attorneys continue to investigate whether manufacturers provided sufficient warnings about the risk of serious dental damage associated with long-term use of these medications.

Nine individuals have filed a lawsuit against Indivior, Indivior Solutions, and Aquestive Therapeutics, alleging that Suboxone’s oral film strips caused severe tooth decay, dental erosion, and other permanent oral injuries.

The complaint, filed on June 5 in the U.S. District Court for the Northern District of Ohio, alleges that the companies failed to adequately warn doctors and patients about the risk of dental damage from the medication.

According to the lawsuit, the plaintiffs allege that the Suboxone film strips expose teeth and gums to acidic ingredients for longer than the company represented.

The complaint claims the strips can take up to 30 minutes to dissolve and may leave residue in the mouth for up to 2 hours, increasing the risk of enamel erosion.

The plaintiffs further contend that Indivior was aware of dental injury reports associated with Suboxone and knew that the film formulation remained in contact with patients’ teeth longer than advertised.

All nine plaintiffs state that they used Suboxone as prescribed to treat opioid addiction and later developed significant dental problems requiring extensive treatment.

The lawsuit brings claims for failure to warn, negligent failure to provide adequate warnings and instructions, and defective design, and seeks compensatory and punitive damages.

The Suboxone MDL added 1 case between May and June, increasing from 1,832 to 1,833.

The docket remained largely unchanged during a month focused on expert discovery and case-specific proceedings involving allegations that Suboxone’s formulation caused severe tooth decay and dental injuries.

While new filings have slowed considerably, the litigation continues to advance toward later-stage pretrial proceedings as the parties develop evidence on causation and damages.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

The Suboxone MDL decreased by 4 cases between April and May, moving from 1,836 to 1,832.

Recent action taken by the MDL judge may prevent some people from joining the litigation.

The MDL judge has stated that Schedule A plaintiffs, those who were able to file abbreviated complaints to preserve their case before the statute of limitations expired, must either file their cases or be dismissed.

Apart from that development, progress is being made toward bellwether trials in the litigation, although they may not commence until 2028.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

A federal judge overseeing the Suboxone multidistrict litigation has ruled that thousands of claims previously filed through “Schedule A” group complaints must now be converted into individual lawsuits or face dismissal.

The Schedule A process had allowed large numbers of plaintiffs to file placeholder claims in bulk to preserve statute of limitations deadlines while gathering medical and dental records.

The court has now indicated that those claims must be formally supported and pursued as individual actions moving forward.

This ruling shifts the litigation toward a more traditional structure, requiring each plaintiff to substantiate their claims with case-specific evidence, including proof of Suboxone use and alleged dental injuries.

Courts overseeing the MDL have stressed the need for complete records and compliance with procedural requirements as the case progresses.

A federal judge overseeing the Suboxone tooth decay multidistrict litigation has clarified that plaintiffs may continue filing claims either individually or in grouped complaints, rejecting arguments that cases must proceed only on a strictly individual basis.

The ruling confirms that the litigation will remain centralized while allowing procedural flexibility for new filings.

The Suboxone litigation is consolidated in the Northern District of Ohio, where thousands of claims allege that the sublingual film formulation caused severe dental injuries.

The court has implemented procedures permitting multiple plaintiffs to file together in a single complaint, streamlining case management while maintaining each claimant’s individual right to damages.

This approach is intended to reduce administrative burden without merging claims into a single lawsuit.

Recent rulings have also addressed the scope of defendants in the litigation.

Certain corporate entities have been dismissed from the proceedings, while claims against other defendants continue to move forward.

These decisions do not eliminate the underlying cases but instead narrow the parties involved.

The court’s guidance ensures that new claims can still be filed and transferred into the multidistrict litigation.

Proceedings remain focused on coordinated discovery and pretrial motions as the litigation advances.

The judge overseeing the federal Suboxone tooth decay litigation has issued a detailed schedule to prepare a small group of cases for early trial dates, with the first bellwether trial expected to begin in March 2028.

All federal cases are centralized in an MDL before Judge Philip Calabrese in Ohio. 

The court is using a bellwether process, meaning a handful of representative cases will go to trial first to show how juries respond to the evidence. 

Those results often guide settlement discussions across the broader litigation.

The selection process is now moving forward in stages. 

From an initial pool of 500 cases, the parties have narrowed the field to 100. 

The court will next reduce that group to 20 cases for deeper discovery, then to 15, and ultimately down to 4 cases that will be tried before juries.

These cases will go through full discovery, including document exchange and depositions, before the final trial pool is selected in mid-2027. 

The first trial is currently scheduled for early 2028.

The lawsuits center on allegations that the manufacturer failed to warn that Suboxone film, placed under the tongue, can cause severe tooth decay and dental damage.

Plaintiffs claim earlier warnings could have helped prevent long-term harm.

The outcome of the bellwether trials will be critical. 

While the results won’t directly decide other cases, they will shape how both sides value the claims and whether a global settlement becomes likely. 

The Suboxone tooth decay lawsuit recorded a decrease in total multidistrict litigation (MDL) cases from March 2026 to April 2026.

The docket declined from 1,849 total cases in March 2026 to 1,836 total cases in April 2026, reflecting a net reduction of 13 cases.

The Suboxone tooth decay lawsuit involves claims that the opioid use disorder treatment drug Suboxone caused severe dental injuries, including tooth decay, tooth loss, and oral infections.

Lawyers are still accepting Suboxone tooth decay lawsuits from individuals in certain states, depending on state-specific statutes of limitation.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Federal multidistrict litigation over Suboxone dental injuries is progressing as courts increase pressure on parties to produce critical medical and pharmacy records.

Judge Philip Calabrese of the Northern District of Ohio is overseeing discovery, requiring plaintiffs and third-party providers to comply with orders to submit documentation linking Suboxone use to tooth decay, enamel erosion, and related dental problems.

Courts have identified a pool of roughly 500 cases from which 100 will be selected for deeper fact-gathering, with 15 designated as potential bellwether trials.

Plaintiffs must submit detailed fact sheets and supporting evidence by April 20, 2026, with defense responses due by May 20, 2026.

These bellwether cases are intended to guide both sides in evaluating the strength of claims and potential settlement values.

A new lawsuit filed in federal court is adding momentum to the growing wave of Suboxone dental injury claims currently pending in multidistrict litigation (MDL) in the Northern District of Ohio.

The complaint, filed by 46 plaintiffs from across the United States, alleges that Suboxone sublingual film strips caused severe tooth enamel damage, dental decay, and tooth loss after prolonged use.

The plaintiffs claim the drug’s manufacturers (Indivior Inc., Indivior Solutions Inc., and Aquestive Therapeutics Inc.) failed to adequately warn patients and physicians about the risk of dental injuries associated with the dissolvable film formulation.

Suboxone, a combination of buprenorphine and naloxone, is widely prescribed to treat opioid use disorder.

While it was originally sold in tablet form, the manufacturers later introduced a dissolvable film strip that patients place under the tongue.

According to the complaint, dental injury reports began emerging after the film formulation entered the market, eventually prompting the FDA to require a warning about tooth decay and other oral health risks on the drug’s label in June 2022.

Plaintiffs also allege the switch from tablets to film strips was part of a broader strategy to protect the drug’s market exclusivity.

The lawsuit claims the manufacturers introduced the film formulation to delay generic competition and encourage doctors to move patients away from the tablet version, even though the dental risks associated with long-term exposure to the dissolvable film had not been adequately studied.

The new case will join thousands of similar claims already consolidated before U.S. District Judge Philip Calabrese as part of the Suboxone film MDL.

The litigation is currently moving through coordinated discovery, with a pool of cases being prepared for future bellwether trials designed to test how juries may respond to the evidence presented by both sides.

Bellwether trial outcomes are expected to play a key role in shaping potential settlement discussions and the overall trajectory of the Suboxone tooth decay litigation moving forward.

The Suboxone MDL decreased by 4 cases between February and March, moving from 1,853 to 1,849.

No new JPML transfer orders or significant docket developments were reported during the month.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The federal judge overseeing the Suboxone film tooth decay litigation has selected 100 lawsuits to move into the next phase of coordinated discovery, marking a key step toward the first bellwether trials.

These cases are part of a multidistrict litigation (MDL) in the Northern District of Ohio before U.S. District Judge Philip Calabrese.

An MDL is a procedure that groups thousands of similar lawsuits before one judge for coordinated pretrial proceedings, helping streamline discovery and avoid inconsistent rulings.

The 100 lawsuits were randomly chosen from a larger pool of 500 cases in which plaintiffs had already produced substantial medical and dental records.

Those selected claims will now undergo “core discovery,” meaning both sides will exchange detailed evidence about dental injuries, prescribing history, warnings, and corporate knowledge.

Under the court’s recent order:

• Plaintiffs must submit Plaintiff Fact Sheets and supporting records by April 20, 2026.

A Plaintiff Fact Sheet is a standardized questionnaire requiring each claimant to provide detailed information about Suboxone use, dental history, and alleged injuries.

• Defendants must provide corresponding defense disclosures by May 20, 2026.

After this discovery phase, the court will narrow the group down to 15 representative cases for early bellwether trials.

Bellwether trials are test cases used to gauge how juries respond to evidence that is common across thousands of similar lawsuits.

While the results are not legally binding on other plaintiffs, they often shape settlement negotiations and case valuation.

The lawsuits allege that Suboxone film, a dissolvable strip containing buprenorphine and naloxone used to treat opioid addiction, caused severe tooth decay, erosion, fractures, and tooth loss because the manufacturer failed to adequately warn about dental risks.

The FDA required a warning about dental injuries in June 2022, after receiving post-market reports of significant oral health complications.

By moving 100 cases into structured discovery and preparing 15 for early trial, the court is signaling that the litigation is entering a more advanced phase.

Judge Calabrese randomly chose 100 plaintiffs in the Suboxone Film MDL for possible inclusion in the Core Discovery Pool under Case Management Order No. 15.

The court chose these cases from files where defendants state that records collection is mostly finished.

Placement in the pool does not mean the cases will go to trial, but it shifts them into a smaller group for more focused, case-specific discovery.

The Core Discovery Pool represents the next step in focusing litigation toward bellwether trials.

By focusing on a specific set of cases with established records, the court can more effectively evaluate claims and start to shape the cases that may ultimately go to trial.

This process frequently facilitates settlement discussions as both sides better understand the strengths and weaknesses of representative claims.

The Suboxone MDL decreased by one case between January and February, slipping from 1,854 to 1,853.

The minimal change reflects routine administrative dismissal or consolidation rather than a shift in filing trends.

No new JPML actions or material docket developments were reported during the month.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Indivior Inc., the manufacturer of Suboxone, has requested that a federal judge consider contempt charges and sanctions against multiple pharmacies and medical providers for failing to comply with court orders to produce patient records in ongoing dental injury lawsuits.

The multidistrict litigation (MDL 3092), centralized in the Northern District of Ohio under Judge Philip Calabrese, established a records collection pool of 500 cases to identify 100 representative cases for discovery.

Compliance problems persist, with several pharmacies and providers refusing to produce records despite repeated court orders.

Last year, Judge Calabrese issued a show cause order, yet nearly a year later, some entities remain non-compliant.

On January 23, 2026, Indivior filed a motion giving remaining non-compliant parties 30 days to produce records or face contempt proceedings or sanctions.

Once records are collected, a final group of approximately 15 cases will proceed as bellwether trials to gauge jury responses.

Outcomes will not be binding but may influence settlements and trial strategies in the broader MDL.

The court recently held a case-management conference to review how the Suboxone litigation is moving forward and to address ongoing discovery issues on both sides.

During the conference, the judge focused on information held by third parties that are not defendants in the case, including medical providers responsible for producing plaintiffs’ records.

The court reviewed compliance with prior orders and discussed whether certain companies failed to turn over required documents, raising the possibility of contempt findings if noncompliance continues.

The court also evaluated how well plaintiffs are meeting their disclosure obligations.

This included updates on the first two rounds of census forms, problems with missing or incomplete responses, and the status of collecting medical records.

The parties reported progress toward completing medical record collection by the end of January.

Defendants provided updates on their own document production.

Issues discussed included missing portions of a non-disclosure agreement, document scanning and formatting problems, and disputes over whether certain materials should remain confidential or be shared more broadly.

Finally, the court addressed scheduling going forward and confirmed logistics for the next status conference.

The discussion reflects the court’s increasing focus on enforcing discovery obligations and keeping the Suboxone litigation on track as it moves into its next phase.

The Suboxone tooth decay lawsuit recorded a decrease in total multidistrict litigation (MDL) cases from December 2025 to January 2026.

The docket declined from 1,871 total cases in December 2025 to 1,854 total cases in January 2026, reflecting a net reduction of 17 cases, which typically indicates dismissals or administrative closures rather than new filings.

The Suboxone tooth decay lawsuit involves claims that the opioid use disorder treatment drug Suboxone caused severe dental injuries, including tooth decay, tooth loss, and oral infections.

Plaintiffs allege that the manufacturer failed to adequately warn patients and prescribers about the risk of serious dental harm associated with Suboxone’s sublingual film formulation.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone tooth decay lawsuit showed no change in total multidistrict litigation (MDL) cases between November 2025 and December 2025.

The docket remained at 1,871 cases for both months, indicating zero new filings during this period.

The Suboxone tooth decay lawsuit involves allegations that prolonged use of the prescription medication Suboxone, formulated as a sublingual film, caused severe dental injuries such as tooth decay, tooth loss, and enamel deterioration.

Plaintiffs claim that product labeling did not adequately warn users about acidic properties that could contribute to dental harm.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

On November 21, 2025, attorneys gathered for a key status conference before U.S. District Judge Philip Calabrese to discuss the current state of the Suboxone tooth decay lawsuits consolidated under MDL No. 3092 in the Northern District of Ohio.

The meeting came as the court continues to oversee more than 5,700 active claims alleging that Suboxone film strips caused severe dental injuries.

Litigation Background

Suboxone, a medication used to treat opioid dependence, became the subject of nationwide litigation after the FDA issued a label change in June 2022 warning about serious dental side effects, including tooth decay, fractures, and enamel erosion.

The lawsuits primarily target the filmstrip version of Suboxone, introduced by Indivior, alleging that the manufacturer failed to warn users about the risks for over a decade.

The litigation argues that Indivior and its parent company, Reckitt Benckiser, knew or should have known about the dental hazards but failed to act until regulators forced them to.

Status Report and Case Reduction

In a November 17 status report submitted to the Court, the Plaintiffs’ Leadership Committee confirmed a significant update to the Schedule A census:

• Original Schedule A Case Count: 8,035
• Dismissed Claims: 2,219
• Remaining Schedule A Claims: 5,763

This reduction reflects the plaintiffs’ efforts to vet cases for viability.

The current count does not include thousands of other claims filed outside Schedule A, many of which were submitted before the summer 2024 statute of limitations deadline.

Discovery and 2026 Scheduling

The parties also submitted a joint agenda addressing:

• Updates on discovery progress and document production
• Proposals to schedule case management conferences for 2026 on January 21 and March 6

The court is continuing to monitor compliance and organization in preparation for large-scale pretrial activities.

Bellwether Trials: The Next Phase

To streamline the litigation, Judge Calabrese is moving forward with bellwether trial planning:

• 500 Cases have been selected for the Records Collection Pool
• From these, 100 Representative Cases will enter a discovery phase
• Eventually, a subset will be chosen for the first bellwether trials

These early trials will not bind other plaintiffs but will provide critical insights into how juries respond to the evidence.

Success in these trials may encourage settlement talks, while failure could trigger thousands of individual trial remands.

What Comes Next

• Additional discovery will proceed through early 2026
• Parties will work toward selecting bellwether cases
• A comprehensive census update is still forthcoming to reflect the total MDL scope

Plaintiffs’ attorneys continue to argue that the risks associated with Suboxone film were long overlooked, and they are pressing for accountability and compensation for the oral damage suffered by thousands of former users.

The Suboxone tooth decay multidistrict litigation saw a slight decline in case count between October and November, dropping from 1,887 to 1,871.

Plaintiffs continue to allege that Indivior failed to warn about dental damage linked to the film formulation of Suboxone.

The claims involve tooth loss, decay, and erosion after prolonged use.

The litigation remains active as discovery progresses and new filings are reviewed by the court.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The federal judge overseeing the Suboxone tooth decay multidistrict litigation (MDL) has issued new case management orders requiring plaintiffs to submit census forms within 60 days of filing suit.

The order, issued by U.S. District Judge Philip Calabrese in the Northern District of Ohio, aims to streamline proceedings and better track the growing number of claims alleging that the Suboxone filmstrip formulation causes severe dental erosion, decay, and tooth loss.

More than 11,000 lawsuits have been filed against manufacturers Indivior and Reckitt Benckiser, accusing them of failing to warn users and healthcare providers that the dissolvable Suboxone film could damage tooth enamel.

The FDA added warning label updates in 2022 after hundreds of patient complaints, triggering a surge in litigation across the country.

Under the new procedures, all cases filed after October 1, 2025, must include a completed census form within 60 days.

The court also set a June 1, 2026, deadline for forms in older cases filed over the prior year.

Meanwhile, both sides are preparing for bellwether trials, beginning with a “records collection pool” of 500 cases that will later be narrowed to 100 for detailed discovery.

These early test trials will help gauge jury reactions and guide potential Suboxone settlement negotiations.

If no resolution is reached, thousands of individual claims could be remanded for trial, underscoring the litigation’s scale and potential impact on future pharmaceutical warning standards.

Between September and October, the number of active cases in the Suboxone tooth decay lawsuit saw a slight decrease, moving from 1,887 to 1,882 cases.

The Suboxone litigation continues to gain national attention as more individuals step forward with dental damage claims allegedly linked to long-term use of the drug.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Judicial Panel on Multidistrict Litigation (JPML) reported 1,882 pending Suboxone lawsuits in September, an increase from 889 pending cases on August 1st.

This reflects an increase of 993 new cases added over the past month.

These lawsuits allege that Suboxone, a medication used to treat opioid use disorder, caused patients to suffer tooth decay, enamel erosion, and other severe dental problems.

Plaintiffs claim that the manufacturer failed to adequately warn of these risks despite knowledge of potential oral health side effects.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

U.S. District Judge Philip Calabrese has issued a show-cause order requiring multiple pharmacies and medical providers to appear in court on August 25, 2025.

This order is intended to get to the root of why these providers have not complied with a prior directive to produce Suboxone prescription records.

The order warns that entities could face contempt findings or sanctions for failing to provide the information.

The affected entities include:

• Albertsons Companies
• Bartell Drugs
• Swedish Pain Services – First Hill
• Boston Medical Center
• Transitions Treatment Program
• Butler Hospital
• Innovative Pain Solutions Center
• Maryland Pain & Wellness Center
• Riverside Treatment Services
• Parkville Pharmacy
• People’s Care Pharmacy
• Prentiss Primary Care
• Scott A. Mayerberger, MD, PC
• Midtown Pharmacy
• Sage Dental of Lake Par
• Care Resources
• AllCare Pharmacy

The records at issue are needed to verify whether plaintiffs in the Suboxone tooth decay litigation were prescribed brand-name Suboxone film strips, and when.

The court previously ordered pharmacies to produce the information within 30 days of receiving a valid medical authorization.

These records are critical to narrowing a group of 500 cases in the “Records Collection Pool” to 100, and eventually to 15 bellwether cases for early trials.

Albertsons Companies has since responded, indicating it was unaware of the motion and has begun producing the required documents.

Other entities named in the order must appear on the scheduled date to address the court.

The Suboxone tooth decay MDL decreased in case filings between July and August, from 890 to 889 filings.

Plaintiffs continue to allege that the medication caused significant dental harm due to its acidic buccal film formulation.

The court is reviewing motions related to pretrial scheduling and the scope of early discovery.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Litigation over dental injuries allegedly caused by Suboxone sublingual film is rapidly expanding, with more than 11,000 lawsuits centralized in multidistrict litigation (MDL 3092) in the U.S. District Court for the Northern District of Ohio.

Judge Philip Calabrese, who is overseeing the MDL, recently issued a new case management order allowing plaintiffs to file complaints using a “block filing mechanism.”

This move enables up to 100 claimants to be joined in a single complaint, streamlining the process and lowering barriers for injured individuals to file claims.

The lawsuits allege that Suboxone, a film-form opioid addiction treatment containing buprenorphine and naloxone, causes severe dental injuries, including tooth decay, enamel erosion, gum disease, and tooth loss.

Plaintiffs claim that the manufacturer, Indivior, failed to warn users and healthcare providers of these risks for years.

A label warning regarding dental harm was not added until June 2022, over a decade after the product’s approval.

In a January 2025 ruling, the court allowed key failure-to-warn claims to proceed while narrowing certain design defect claims.

The decision followed the submission of scientific studies and adverse event reports linking Suboxone’s acidic formulation to long-term dental damage.

A December 2022 research letter published in JAMA reported that users of sublingual buprenorphine had more than twice the rate of dental problems compared to those taking other forms of the drug.

Bellwether trials are expected to begin in late 2025 or early 2026.

These trials are intended to help both parties gauge the strength of claims and defenses, and may influence future settlement discussions.

Suboxone lawsuits continue to be filed in the MDL, particularly after the court’s recent filing order aimed at expediting the litigation process.

At the latest status conference, the judge overseeing the Suboxone MDL approved several agreements on how the parties will manage documents and new claims moving forward.

This includes redacting old deposition transcripts, finalizing medical release forms, and tracking claims filed after October 7, 2024.

The parties also discussed how to handle document production from key individuals.

Judge Calabrese resolved two disputes about the wording of Rule 30(b)(6) deposition notices and asked the parties to continue working on another unresolved document issue.

Two deadlines were established: one for submitting a plan to gather non-custodial documents, and another for submitting fact sheets detailing claims and defenses.

The upcoming in-person hearing is set for September 9.

On July 14, 2025, U.S. District Judge Philip Calabrese reappointed nearly 30 attorneys to continue leading the federal Suboxone tooth decay litigation centralized in the Northern District of Ohio.

The leadership team will oversee pretrial proceedings, coordinate discovery, and manage bellwether trial preparations in the growing multidistrict litigation (MDL No. 3092).

The reappointment came ahead of a case management conference scheduled for July 15, 2025, where the court is expected to address the ongoing selection and development of bellwether cases.

Currently, over 11,000 lawsuits have been consolidated in the MDL, all involving allegations that Suboxone caused severe tooth decay, tooth loss, and oral damage, and that the manufacturer failed to adequately warn users and healthcare providers.

The litigation is proceeding through an organized bellwether process.

A records collection pool of 500 cases was established earlier this year, with 100 lawsuits selected for more detailed discovery.

That group will later be narrowed to 15 cases, from which five will be selected for early jury trials intended to gauge potential outcomes and drive settlement discussions.

If no global resolution is reached following the bellwether trials, individual cases may be remanded back to their original jurisdictions for trial.

The Suboxone MDL saw a slight decrease in filings, dropping from 896 in May to 892 in June.

The dip may reflect case consolidation or clerical corrections, but overall, the litigation remains active.

Plaintiffs continue to allege that prolonged use of Suboxone film strips—formulated with buprenorphine—led to severe dental injuries including tooth loss, decay, and jaw deterioration.

Lawyers are awaiting rulings on Daubert motions that could shape the admissibility of expert testimony on Suboxone’s acidic pH and its corrosive impact on enamel.

The next case management conference is expected to address scheduling for early bellwether trials.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

On May 19, Judge Philip Calabrese approved the process for selecting 50 Suboxone dental claims that will proceed in the bellwether discovery phase.

These cases will come from a previously identified Records Collection Pool comprising 500 lawsuits, all alleging that the Suboxone film caused severe tooth decay and dental injuries.

The court will randomly select 100 cases from the larger pool to create a Core Discovery Pool.

From there, each side will choose 15 claims, and the court will randomly select another 20, finalizing a group of 50.

These 50 cases will undergo targeted discovery and be eligible for selection into a final trial pool of 15 bellwether cases.

The court has not set dates for selecting the trial pool.

The next MDL status conference is scheduled for June 17.

Parties are required to submit an agenda by June 13.

The Suboxone Lawsuit involves claims that the opioid addiction treatment medication has caused severe dental issues, including tooth decay, enamel erosion, and tooth loss.

Plaintiffs allege that manufacturers failed to adequately warn users and healthcare providers about the risk of dental damage associated with long-term Suboxone use.

No new cases were added to the Suboxone MDL in the past month.

The total number of filings remains at 896.

Despite the filing plateau, the litigation remains active as affected individuals continue to seek accountability for their dental injuries.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone tooth decay multidistrict litigation (MDL) is advancing as the court initiates the record collection phase for potential bellwether cases.

500 plaintiffs have been randomly selected to form a “Record Collection Pool,” which includes 100 filed cases and 400 on tolling agreements.

These plaintiffs are now required to provide authorizations allowing defendants to obtain their medical records.

This phase will conclude once 85% of the records are obtained, which is expected to take about six months.

Once that point is reached, the parties will begin identifying specific cases for early bellwether trials, which will help evaluate how juries may respond to recurring claims that Suboxone film caused severe dental damage.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

As the June 2025 deadline for filing Suboxone lawsuits approaches in states with a three-year statute of limitations, thousands of individuals who have experienced tooth decay and other dental issues due to Suboxone use are expected to take legal action.

Suboxone, which has been prescribed for opioid addiction treatment, has been linked to severe dental damage, including tooth decay and loss, particularly among users of the sublingual film version.

The manufacturer, Indivior, updated the drug’s warning label in June 2022, acknowledging the risks of tooth decay and dental erosion for the first time.

This prompted a wave of lawsuits, leading to the consolidation of over 10,000 claims in a multidistrict litigation (MDL).

Many of the affected users were not aware that their dental issues were linked to Suboxone until after the label update, leading to confusion about when the statute of limitations should begin.

As a result, individuals in states with a three-year statute of limitations are racing against time to file their claims by June 2025.

Failure to meet the statute of limitations could prevent them from seeking compensation for their injuries.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone Tooth Decay Lawsuit remained steady from March to April 2025, with no new cases filed during this period.

Both months reported a total of 896 cases.

The Suboxone Lawsuit centers on claims from individuals who allege that long-term use of Suboxone, a medication used for opioid addiction treatment, contributed to severe dental issues, including tooth decay and other oral health problems.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The U.S. District Judge overseeing Suboxone lawsuits has approved a bulk filing process, allowing up to 100 plaintiffs with tooth decay claims to be included in a single lawsuit.

This move aims to streamline case management and reduce filing fees as the litigation expands.

The decision comes as the three-year anniversary of the FDA’s 2022 tooth decay warning approaches, potentially creating filing deadlines in some states.

Suboxone manufacturers have argued that the statute of limitations may bar claims not filed before June 2025.

Suboxone lawsuits are centralized in a multidistrict litigation (MDL) in the Northern District of Ohio under Judge Philip Calabrese, where more than 10,000 cases are pending.

The bulk filing order follows a similar Schedule A case from last year, which grouped 9,600 plaintiffs to prevent court overload.

In addition, the court has ordered the creation of a Record Collection Pool, selecting 500 random plaintiffs for medical record gathering.

Meanwhile, bellwether trials are being planned to help assess potential jury verdicts and influence settlement discussions.

While early trials won’t be binding, the average payouts from these cases could impact future Suboxone settlements, potentially leading to a resolution before individual trials proceed.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

In March 2025, the number of new filings in the Suboxone tooth decay litigation remained unchanged at 896 cases, showing no increase from the 896 cases reported in February 2025.

However, February had experienced a drop of 142 cases compared to the previous month.

Our lawyers are actively monitoring developments in the Suboxone Lawsuit and we are still helping those impacted seek compensation for the harm caused by Suboxone-related tooth decay.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

A federal judge overseeing the Suboxone tooth decay lawsuits has ordered pharmacies and medical providers to produce requested medical records within 30 days.

The ruling aims to prevent delays in the growing litigation.

More than 11,000 lawsuits claim that Suboxone film caused severe tooth decay. Plaintiffs’ lawyers are working to gather dental records and prescription history to identify cases for early bellwether trials.

However, difficulties in obtaining these records have slowed progress.

Some providers have imposed inconsistent authorization requirements, making it harder for plaintiffs to access necessary documentation.

Judge Philip Calabrese is managing the multidistrict litigation (MDL) in the Northern District of Ohio.

His ruling requires medical providers to accept electronic or ink-signed authorizations.

They cannot impose additional requirements, such as photo ID requests, that would further delay production.

The next status conference is set for March 11.

More Suboxone lawsuits are expected before the three-year anniversary of the FDA’s 2022 label update on tooth decay risks.

These early trials will help determine potential settlements or case outcomes.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone (buprenorphine/naloxone) Film Products Liability Litigation, MDL 3092, is currently in the process of developing its bellwether protocol for trial cases.

This MDL, which consolidates claims against the manufacturers of Suboxone Film for alleged dental injuries, is taking steps toward organizing discovery procedures, including setting up the Bellwether Pool of cases.

The Plaintiffs’ Liaison Counsel (PLC) has proposed expanding the core discovery pool to 50 plaintiffs and potentially up to 250 depositions before bellwether cases are selected for trial.

The PLC is also negotiating with the defendants on the timeline for producing necessary documents and custodial files.

Additionally, a proposed case management order outlines the process for selecting bellwether cases.

A pool of 100 cases will be randomly selected, and plaintiffs will need to submit specific documentation, including proof of Suboxone use and dental injuries.

The bellwether process will follow a structured timeline, culminating in trial workup in 2026.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

In February 2025, the number of Suboxone Tooth Decay Lawsuits pending in the MDL rose to 896, an increase of 142 filings compared to the 754 cases in January 2025.

Plaintiffs claim that the medication, commonly used for opioid addiction treatment, has caused significant tooth decay and oral health complications.

The substantial rise in filings suggests that more individuals are coming forward with similar experiences and seeking compensation for the harm caused.

As awareness of the potential dental side effects of Suboxone grows, the litigation continues to expand as those affected seek justice for their oral health damages.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone multidistrict litigation (MDL) is poised for a significant increase in case filings as a potential statute of limitations deadline approaches in June 2025.

Individuals in states with a three-year limitations period could face their final opportunity to file claims against the makers of Suboxone, an opioid addiction treatment linked to severe dental problems, including tooth decay and erosion.

U.S. District Judge Philip Calabrese, presiding over the Suboxone MDL in the Northern District of Ohio, has indicated that the court is preparing for a wave of new lawsuits.

Plaintiffs and defendants have been unable to agree on tolling measures to manage the anticipated filings, leaving each claimant to file individually before the deadline.

The MDL, established in 2024, has centralized over 10,000 claims that allege the drugmaker failed to warn users and healthcare providers about the risks of tooth damage associated with Suboxone sublingual film.

The warnings were not added until June 2022, after an FDA mandate, sparking allegations that earlier disclosures could have prevented widespread and permanent dental harm.

The litigation has already seen a bundled complaint in 2024, involving over 9,500 plaintiffs from states with shorter statutes of limitations.

The surge in filings may also test the court’s capacity to process claims efficiently.

With nearly 8,600 cases remaining from the initial bundle and thousands more anticipated, potential claimants are encouraged to act promptly to ensure their cases are filed before the June 2025 deadline.

Early participation in the litigation could provide access to compensation for dental treatment, pain, and other damages caused by Suboxone-related injuries.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Teva Pharmaceuticals is actively pursuing efforts to dismiss cases before settlement talks advance further.

In a recent move, Teva responded to a Show Cause Order from the Northern District of Georgia by identifying deficiencies in a plaintiff’s documentation.

The company issued a Deficiency Letter, emphasizing unmet procedural requirements.

This approach underscores Teva’s broader strategy of enforcing strict compliance with procedural standards, potentially reducing the number of active claims.

Meanwhile, progress toward a global settlement continues.

Sixteen months ago, M. Gino Brogdon Sr., a retired judge, was appointed to oversee settlement negotiations as part of the multidistrict litigation (MDL).

Mediators play a crucial role in facilitating resolutions in complex MDLs, and it is anticipated that Brogdon’s involvement will intensify as 2025 unfolds.

While hopes remain high for a global settlement to resolve most claims before trial, the timeline for resolution remains uncertain.

Both plaintiffs and defendants face critical junctures, with procedural diligence and proactive negotiation efforts expected to shape the outcome of this high-profile litigation.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone MDL is making significant strides after the judge ruled on the Motion to Dismiss, which resulted in a ruling that was about 80% favorable to the Plaintiffs.

The court allowed key claims, such as failure to warn and design defects, to move forward against the manufacturer.

However, the design defect claim for post-2010 cases has been dismissed.

Plaintiffs will still pursue failure to warn claims, which will extend to 2022, but these claims are now limited to defendant Indivior, the company responsible for the drug’s labeling.

Although there were some unfavorable outcomes concerning Indivior, overall, this ruling is a substantial win for plaintiffs pursuing compensation in the Suboxone Tooth Decay Lawsuits. 

The case is now entering a new phase, focusing on discovery, expert testimony, and bellwether trial selections. 

The next Case Management Conference (CMC) is scheduled for January 14, 2025, and will offer more clarity on the roadmap for the remainder of 2025, which should bring further developments in this complex litigation.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The number of Suboxone Lawsuits pending in the Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation has increased from 716 in December to 754 in January 2025, reflecting an increase of 38 new cases.

Suboxone, a prescription medication commonly used in the treatment of opioid addiction, is at the center of litigation due to findings that the sublingual form of the medication causes severe tooth decay.

The rise in case filings underscores the growing legal action against the manufacturers of Suboxone as more individuals who have suffered from its adverse effects seek compensation.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone mass tort litigation reached a critical stage this week as oral arguments were presented for the Defendants’ Motion to Dismiss.

Filed in June 2024, the motion hinges on the preemption defense, a common argument in mass tort cases involving FDA-approved products.

Lawsuits involving products like prescription drugs, manufacturers can argue that they cannot be held liable under state laws because the products were approved by the federal government, such as the FDA (Food and Drug Administration).

Defendants assert that the FDA’s approval of Suboxone and the absence of verified adverse event reports tied their hands, preventing label modifications from disclosing the alleged risk of tooth decay.

Plaintiffs counter that FDA approval does not absolve manufacturers of their ongoing duty to monitor, report, and disclose risks, including tooth decay, allegedly linked to Suboxone use.

Judge Calabrese is expected to rule on the Motion to Dismiss before the next Case Management Conference, scheduled for January 14, 2025. 

A ruling in favor of the Plaintiffs would allow the litigation to proceed toward discovery and potential trials, advancing claims for compensation over Suboxone-related dental injuries.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The federal judge overseeing over 11,000 Suboxone tooth decay lawsuits heard oral arguments on December 16 regarding the drug maker’s motion to dismiss the claims, which centers on federal preemption.

Indivior, the manufacturer of Suboxone film, argues that federal law barred it from updating warning labels earlier, which should prevent users from pursuing state-based failure-to-warn claims.

The lawsuits allege that Indivior failed to warn about the risk of severe dental damage, including tooth decay and enamel loss, despite widespread reports of these issues prior to a label update in June 2022.

Plaintiffs argue that Indivior had the responsibility to alert users and the medical community to these risks and contend that safer alternatives for delivering the drug’s active ingredients were available.

The cases have been centralized in a multidistrict litigation (MDL) before U.S. District Judge Philip Calabrese in the Northern District of Ohio.

While the judge did not issue a ruling on the motion to dismiss, he has scheduled additional case management conferences for April, May, and June 2025 to keep the litigation moving forward.

If the motion to dismiss is denied, the Court is expected to select representative bellwether cases for early jury trials.

While these trials will not bind other claims, they could significantly influence future Suboxone settlements, as jury verdicts will guide negotiations to resolve the remaining lawsuits.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Oral arguments over a motion to dismiss more than 11,000 Suboxone Tooth Decay Lawsuits are scheduled for December 16, with Indivior, the drug’s manufacturer, arguing that federal law preempted its ability to update the drug’s warning labels before June 2022.

Suboxone Lawsuits allege that Indivior failed to warn about the drug’s potential to degrade tooth enamel, leading to widespread issues such as dental decay, cavities, oral infections, and tooth loss.

Plaintiffs contend that Indivior knew or should have known about these risks but continued to market Suboxone, a sublingual film designed for opioid addiction treatment, without providing adequate warnings or preventive guidance..

Suboxone Tooth Decay Lawsuits have been centralized into multidistrict litigation (MDL) before U.S. District Judge Philip Calabrese in the Northern District of Ohio for coordinated pretrial proceedings.

Judge Calabrese will hear oral arguments on December 16, following a status conference held in November.

The court has requested a joint report by December 12 outlining any additional issues for consideration.

If the motion to dismiss is denied, the MDL will likely proceed with the selection of bellwether cases to represent the broader litigation in early trials.

These trials, while not binding on the remaining claims, could influence the settlement amounts Indivior may be required to pay to resolve the lawsuits without individual jury trials.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Judicial Panel on Multidistrict Litigation (JPML) reported 678 case filings for the Suboxone Tooth Decay lawsuit in November.

By December, the number of case filings increased to 716, reflecting a growth of 38 cases.

The Suboxone Tooth Decay lawsuit involves allegations that the opioid addiction treatment Suboxone caused severe dental issues, including tooth decay and loss, despite insufficient warnings from the manufacturer about these risks.

The rise in filings may result from growing awareness among patients and healthcare providers about the connection between Suboxone use and dental injuries.

The litigation continues to evolve as additional plaintiffs come forward, seeking accountability for the alleged harm caused by the medication.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The U.S. District Judge overseeing the Suboxone tooth decay litigation has issued guidelines for conducting a complete census of all pending claims.

This census aims to provide an overview of cases and identify representative claims that may proceed to early bellwether trials, which will assist the parties in evaluating potential jury responses.

Over 11,000 lawsuits have been filed against Indivior, alleging that Suboxone’s sublingual film caused significant dental damage, including tooth decay and enamel erosion, which plaintiffs claim was inadequately disclosed.

Despite Suboxone being on the market for over a decade, warnings regarding dental risks were not added to the drug’s label until June 2022. 

Plaintiffs argue that this delay contributed to preventable dental injuries.

The lawsuits have been consolidated into a multidistrict litigation (MDL) under U.S. District Judge Philip Calabrese for streamlined pretrial proceedings.

This includes coordinated discovery and planned bellwether trials, intended to provide insight into jury reactions to common evidence.

Following a two-day conference in October 2024, Judge Calabrese issued a case management order detailing the census protocols.

This census will cover individually filed lawsuits and bundled Schedule A cases submitted this summer, but excludes cases filed after October 7, 2024.

These proceedings mark significant steps in advancing the litigation and determining fair compensation for Suboxone users who suffered dental harm.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone Tooth Decay Lawsuit centers on claims that the opioid addiction treatment drug Suboxone has led to unexpected dental issues, including severe tooth decay, erosion, and loss.

Plaintiffs allege that the manufacturer, Indivior, failed to adequately warn users about the potential for significant dental damage as a side effect of using Suboxone.

In October, there were 674 cases filed in connection with Suboxone tooth decay claims.

By November, that number increased slightly to 678, adding 4 new cases.

This steady rise reflects continued awareness among users about the potential dental risks associated with long-term use of Suboxone.

Suboxone’s impact on dental health can lead to painful and costly dental procedures, significantly affecting the quality of life for those relying on the medication for opioid addiction treatment.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

A multi-day status conference for the Suboxone Tooth Decay Lawsuit began on October 4, 2024, bringing together plaintiffs, defendants, and the MDL judge overseeing Suboxone dental injury cases to finalize protocols for upcoming discovery and early bellwether trials.

Currently, over 11,000 claims allege that Suboxone, a medication designed as a sublingual film, caused severe dental issues, including tooth decay and enamel degradation, due to insufficient warnings by the drug manufacturer, Indivior.

Central to this case management conference is the development of a comprehensive census protocol, where plaintiffs are required to submit detailed information on their injuries.

This census is intended to assist the court in identifying cases that are broadly representative of the ongoing claims, facilitating the selection of specific cases for initial bellwether trials.

These early trials will provide insights into how juries might respond to evidence and testimony related to Suboxone’s dental injury risks.

In response to mounting reports, the FDA updated Suboxone’s labeling in June 2022 to include warnings about potential dental damage linked to the drug.

Plaintiffs argue that if Indivior had provided earlier warnings and usage instructions, users could have prevented severe dental injuries.

During the conference, discussions include the procedural steps for gathering additional case details, medical records, and adverse event reports.

These early trials will proceed with extensive discovery, including expert testimony on Suboxone’s role in causing dental harm.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

The Suboxone Tooth Decay Lawsuit focuses on claims that the drug, used to treat opioid addiction and opioid use disorder (OUD), causes severe dental issues, including tooth decay, loss, and other oral health problems.

Plaintiffs argue that Suboxone manufacturers failed to provide adequate warnings about the drug’s side effects, specifically its potential to cause serious dental damage.

In both September and October, the Judicial Panel on Multidistrict Litigation (JPML) reported 674 active Suboxone tooth decay lawsuits.

Suboxone users have reported severe dental problems, including rapid tooth decay and tooth loss, which require costly treatments such as root canals, dentures, or implants.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

In a recent update on the Suboxone MDL, an Ohio federal judge dismissed Indivior PLC and two Reckitt Benckiser entities from the ongoing lawsuits alleging that Suboxone, an opioid addiction treatment, caused dental decay.

U.S. District Judge J. Philip Calabrese issued the order following an agreement reached between the parties involved.

The dismissal is with prejudice in the case filed by plaintiff Ryan Bennett, meaning the claim cannot be refiled, while it is without prejudice for other cases in the MDL, allowing those claims to potentially be brought again in the future.

The litigation centers on allegations that the companies failed to warn consumers about the acidic properties of Suboxone’s dissolvable film, which could harm patients’ teeth.

The MDL, initially consolidated in February 2024, now includes claims from multiple states, and while Indivior and Reckitt Benckiser have been dismissed, the litigation continues against other defendants like Aquestive Therapeutics Inc.

This follows Indivior’s prior settlement of antitrust claims over Suboxone in a separate case.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a Suboxone lawyer.

The Suboxone Lawsuit, which saw significant activity earlier this year due to concerns about a potential statute of limitations, has been relatively quiet recently.

However, this is expected to change as we approach the end of 2024.

The pace of the litigation is likely to pick up as defendants are scheduled to produce key documents and custodial files that plaintiffs are expected to receive before year-end.

A pivotal moment in this litigation will occur on October 4, 2024, when the oral argument for the Defendants’ Motion to Dismiss (MTD) based on preemption will occur. 

If the plaintiffs successfully challenge the MTD, the litigation will move forward rapidly, with a bellwether trial process likely to be agreed upon, and defendants will begin to receive further case-specific disclosures.

This could mark a major turning point in the Suboxone Tooth Decay Lawsuit, setting the stage for substantial developments in the coming months.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit instantly. 

The Suboxone Tooth Decay Lawsuit, which involves claims that the use of the medication Suboxone has led to severe dental issues, continues to see a slight increase in filings.

In August 2024, there were 673 active cases in the Suboxone tooth decay lawsuit.

By September 2024, this number has increased marginally to 674.

Plaintiffs in this lawsuit allege that Suboxone users have experienced significant tooth decay, even with proper dental hygiene, and that the manufacturer failed to provide adequate warnings about these risks.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

The Suboxone Lawsuit involves claims against the drug’s manufacturer related to an increased risk for severe tooth decay and other dental injuries.

In July, there were 677 filings in the Suboxone lawsuit.

By August, this number decreased slightly to 673 filings.

Suboxone, used to manage opioid addiction, has been linked to severe tooth decay, including cavities, tooth loss, and other dental issues.

Many affected individuals have filed lawsuits against Indivior for not adequately warning about these dental risks, leading to significant health complications and financial burdens for dental treatments.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Key dates for the Suboxone Tooth Decay Lawsuit are fast approaching

Suboxone Lawsuits are advancing with submission dates in August 2024 and a potential settlement timeline extending into mid-2025.

The litigation is continuing to grow and lawyers are still accepting new Suboxone claims.

In June 2024 there were 258 Suboxone Lawsuit filings reported by the JPML.

By July 2024 the number of Suboxone Lawsuits had increased to 677.

• Key Submission Dates:
  • Claim information and party proposals due on August 16 and 27, 2024.
  • These documents are vital for progressing the litigation and may significantly impact the direction of the case.
• Settlement Timeline:
  • Settlement discussions expected to extend into mid-2025.
  • Earliest potential settlement by June 2025, pending resolution of ongoing issues within the litigation.
• Tolling Agreement:
  • Progress report due on August 1, 2024.
  • The tolling agreement pauses the statute of limitations, allowing time for comprehensive case preparation.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone Tooth Decay Lawsuit is ongoing, and our lawyers are actively accepting cases from those affected by dental issues linked to Suboxone. 

The number of Suboxone Lawsuits has increased as more patients have come forward to report severe tooth decay and other dental problems associated with the medication, seeking legal support from Suboxone Lawyers.

Suboxone Tooth Decay Lawsuits involve claims of dental injuries resulting from the use of the drug, a medication used for opioid addiction treatment.

The core arguments in the Suboxone Tooth Decay Lawsuits revolve around:

• Failure to Warn: Plaintiffs argue that the manufacturers did not provide adequate warnings about the risk of severe tooth decay associated with Suboxone.
• Negligent Design: Allegations include that the design of Suboxone contributes to an increased risk of dental problems, including tooth decay.
• Lack of Adequate Instructions: Many lawsuits claim that the manufacturers failed to provide proper instructions on how to minimize dental risks while using Suboxone.

In response to the increasing litigation, healthcare professionals recommend the following precautions for those using Suboxone:

• Maintain Oral Hygiene: Follow a strict oral hygiene routine, including brushing and flossing regularly.
• Regular Dental Check-Ups: Schedule frequent dental check-ups to monitor and address any early signs of tooth decay.
• Discuss with Your Doctor: Talk to your healthcare provider about the potential dental risks and ways to mitigate them while using Suboxone.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

The Suboxone lawsuit involves claims that the opioid addiction treatment drug Suboxone has caused severe dental issues, including tooth decay, tooth loss, and other dental problems.

This lawsuit seeks to hold the manufacturer accountable for these adverse effects.

In June, there were 258 Suboxone lawsuit filings.

By July, this number increased to 677.

Suboxone can cause significant dental problems, leading to tooth decay and tooth loss. These issues have prompted more individuals to join the Suboxone lawsuit.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit.

Contact TorHoerman Law for a free consultation.

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Over 9,600 new plaintiffs joined the lawsuit against the makers of Suboxone in a mass filing, just before a potential deadline that could have impacted claims in many states.

Suboxone, a treatment for opioid addiction, has been linked to severe dental issues, including tooth decay and permanent damage.

Suboxone, containing buprenorphine and naloxone, has been widely used to help manage opioid withdrawal symptoms.

Initially approved in tablet form in 2002, a sublingual film version was introduced around 2012.

Plaintiffs allege that the film version was developed to delay competition from generics and lacked adequate warnings about dental risks.

The FDA only required a tooth decay warning after June 17, 2022, following numerous complaints of tooth loss.

With the second anniversary of the FDA label update approaching, approximately 500 Suboxone Lawsuits were already pending in federal courts.

U.S. District Judge Philip Calabrese in the Northern District of Ohio is overseeing these cases as part of a multidistrict litigation (MDL) established in February 2024 for coordinated discovery and pretrial proceedings.

Judge Calabrese will likely establish a “bellwether” process to select representative claims for early trials.

The outcome of these trials will influence settlement negotiations.

If you or a loved one used Suboxone and suffered severe tooth decay, you may be eligible to file a Suboxone Lawsuit. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Suboxone Tooth Decay Lawsuit instantly. 

The U.S. District Judge overseeing the consolidated Suboxone dental decay lawsuits has initiated a Leadership Development Committee (LDC) to streamline case management and enhance legal representation across the MDL.

This committee is part of the mass tort litigation process, focusing on the widespread claims that Suboxone film causes severe dental decay, a side effect previously undisclosed by the drug’s manufacturer.

Suboxone is a medication used to treat opioid addiction, but the sublingual film version of the drug introduced in 2012 has been linked to significant dental health issues, including enamel erosion, tooth decay, cavities, oral infections, and loss of teeth.

It wasn’t until June 17, 2022, that the FDA mandated warnings about the risk of tooth decay on the medication’s labeling, spurred by numerous patient complaints.

Plaintiffs allege that an earlier warning could have prevented irreversible dental damage.

Approximately 350 product liability lawsuits are pending in the MDL, with numbers expected to surge as the two-year anniversary of the label update approaches, signaling a potential deadline for new claims.

These cases have been centralized in the Northern District of Ohio under Judge Philip Calabrese for coordinated pretrial proceedings.

If you or a loved one used Suboxone and suffered severe tooth decay, you may be eligible to file a Suboxone Lawsuit. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Suboxone Tooth Decay Lawsuit instantly.

Currently, 258 lawsuits are consolidated under the Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation, as per the latest Judicial Panel on Multidistrict Litigation (JPML) records.

These lawsuits allege that Suboxone, particularly in sublingual film or tablet form, increases the risk of severe tooth decay due to prolonged exposure of the teeth to decay-promoting substances.

The Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation centralizes claims that Suboxone leads to severe dental issues in a single federal court.

If you or a loved one used Suboxone and suffered severe tooth decay, you may be eligible to file a Suboxone Lawsuit. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Suboxone Tooth Decay Lawsuit instantly.

Plaintiffs continue to push for a tolling agreement to manage the administration of this multi-district litigation (MDL).

Since November 2023, plaintiffs have argued for the necessity of such an agreement to temporarily suspend the statute of limitations, allowing the filing of additional claims related to dental injuries from Suboxone.

As of May 2024, nearly 500 cases are pending.

Plaintiffs warn that without a tolling agreement, the court faces a surge of potentially unapproved claims that could lead to complications and undermine the MDL’s goal of streamlining proceedings.

The defendants have consistently rejected the tolling agreement.

This stance is viewed by the plaintiffs as a strategy to increase the litigation burden, potentially discouraging the filing of weaker claims and complicating the MDL process.

The controversy also involves the Suboxone warning label, which was updated on June 17, 2022 under FDA guidance to warn of the risks of dental decay and tooth erosion.

The plaintiffs’ proposal that the court forces defendants to respond to each complaint suggests an attempt to pressure the defendants into accepting the tolling agreement, aiming to manage their caseload more efficiently among concerns of “blind filing” claims that may later be dismissed as meritless.

The court’s impending decisions could significantly influence the proceedings in the Suboxone Tooth Decay litigation, potentially impacting how both parties manage their strategies for the lawsuit.

Our law firm is still accepting new clients for the Suboxone Tooth Decay Lawsuit. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Suboxone Tooth Decay Lawsuit instantly.

A total of 205 lawsuits are pending in the Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation according to the most recent JPML filings.

Just 44 Suboxone Lawsuits were pending in the MDL on April 1st, showing an increase of 161 cases sent to the litigation in the past month.

Lawsuits claim that the formulation of Suboxone, particularly when taken as a sublingual film or tablet, can lead to increased exposure of the teeth to harmful substances that promote decay.

The Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation groups lawsuits claiming that Suboxone causes severe tooth decay into one federal court.

If you or a loved one used Suboxone and suffered severe tooth decay, you may be eligible to file a Suboxone Lawsuit. 

Contact TorHoerman Law for a free consultation. 

You can also use the chatbot on this page to find out if you qualify for the Suboxone Tooth Decay Lawsuit instantly. 

According to the latest JPML update, the number of Suboxone Lawsuits pending has decreased to 44 as of April 1st, from 51 reported on March 1st.

People who have used Suboxone to treat opioid addiction are filing lawsuits against the manufacturers of the drug due to claims of severe tooth decay and other dental injuries.

The FDA required the manufacturers of the drug to put warning labels on individual boxes of Suboxone in 2022, but many people were not warned of the potential for dental problems before this.

If you or a loved one took Suboxone and suffered severe tooth erosion or other dental issues, you may be eligible to file a Suboxone Tooth Decay Lawsuit. 

You can also use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit. 

The United States District Court for the Northern District of Ohio has streamlined the process for filing lawsuits related to dental injuries from Suboxone film by allowing plaintiffs to file their cases directly in this court, as part of the larger Multidistrict Litigation (MDL) No. 3092.

Suboxone is a prescription medication used to treat opioid addiction, combining buprenorphine, which reduces withdrawal symptoms, with naloxone to deter misuse.

Suboxone use, specifically forms of the drug that dissolve in the mouth, carries risks such as severe tooth decay, cavities, and tooth loss.

The direct filing system is designed to speed up the legal process by bypassing the need for lawsuits to be transferred from various courts to this central location.

Plaintiffs have the option, but are not required, to directly file their lawsuits in this MDL.

Attorneys from across the United States can represent their clients in this MDL without needing to obtain special permission or pay additional fees, further simplifying the legal proceedings for plaintiffs.

In their filings, plaintiffs are asked to suggest a preferred trial location based on personal connections to the case, such as where they live, where they were prescribed Suboxone, or where they used it.

This does not guarantee that the trial will take place in the suggested location but helps in organizing the cases within the MDL framework.

This directive from the Northern District of Ohio is a significant step towards making the legal process more accessible and efficient for individuals seeking justice for dental injuries allegedly caused by Suboxone film and Suboxone tablets dissolved in the mouth.

If you or a loved one used Suboxone and subsequently developed dental issues, tooth decay, oral infections, or other dental injuries, you may be eligible to file a Suboxone Tooth Decay Lawsuit.

Contact TorHoerman Law for a free consultation, or use the chatbot on this page to find out if you qualify for the Suboxone Lawsuit instantly.  

As of March 19th, the consolidated Multidistrict Litigation (MDL) for Suboxone Tooth Decay has grown to 51 cases.

MDLs serve as a critical mechanism for efficiently managing lawsuits that share common issues, such as those involving pharmaceuticals, defective products, and complex legal disputes.

By centralizing cases involving tooth decay from Suboxone use, MDL streamlines discovery, leverages shared evidence and accelerates the progress of individual claims.

The transition of Suboxone Lawsuits into an MDL marks a pivotal development in their management and potential resolution.

Consolidation allows for a pooling of resources, enabling a more concentrated legal strategy that benefits from extensive expert analysis and investigative efforts.

Within the scope of the Suboxone Tooth Decay Lawsuit, individuals affected by dental issues following Suboxone usage have the opportunity to seek legal redress and potentially participate in a collective action aimed at securing compensation.

The establishment of an MDL in this context underscores the commitment to achieving justice for victims who have suffered dental damage as a consequence of their addiction treatment.

If you or someone close to you has experienced severe dental issues as a result of taking Suboxone, you might be entitled to take legal action. 

Utilizing the chatbot available on this page can guide you in determining your eligibility to file a Suboxone Lawsuit and connect you with a qualified Suboxone attorney.

The Judicial Panel on Multidistrict Litigation (JPML) has consolidated Suboxone Tooth Decay Lawsuit in the Northern District of Ohio.

Eleven cases have been consolidated into the newly created MDL, according to the most recent JPML filings.

Multi-District Litigations (MDLs) are legal procedures in the United States designed to handle multiple related civil lawsuits that involve similar issues, facts, or defendants.

When numerous individuals or entities file lawsuits related to a common set of circumstances, such as product liability, pharmaceuticals, or mass tort cases, these cases can be consolidated into a single federal district court for pretrial proceedings.

MDLs aim to streamline the litigation process by centralizing the discovery process, reducing duplication of efforts, and ensuring consistent rulings on key legal issues.

In the context of the Suboxone Tooth Decay Lawsuit, this means that those suffering from dental issues after taking Suboxone may be able to file a claim and take part in a mass tort litigation with the aim of compensation.

The formation of an MDL for Suboxone Tooth Decay is a significant step in seeking justice for those who have suffered tooth decay and other dental injuries from the opioid addiction treatment.

If you or a loved one took Suboxone and subsequently suffered severe tooth decay, you may be eligible to take action and file a Suboxone Lawsuit. 

Contact TorHoerman Law for a free consultation. 

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit and to get in touch with a licensed Suboxone lawyer.

Suboxone Lawsuits are currently being filed on behalf of those who have suffered tooth decay and other dental injuries. 

The Suboxone Tooth Decay Lawsuits are poised to be officially consolidated into multidistrict litigation (MDL).

Following petitions to the Judicial Panel on Multidistrict Litigation (JPML) last month, the drug manufacturers named in the tooth decay lawsuits agreed to consolidation.

This is a major step in seeking justice and compensation for those who have suffered tooth damage and decay subsequent to taking Suboxone.

Our law firm is currently speaking to potential clients about their situations and assessing eligibility to file Suboxone Tooth Decay Lawsuits.

Reach out to us for a free consultation. 

Use the chatbot on this page to find out if you qualify to file a Suboxone Lawsuit claim instantly.

Attorneys representing individuals who have suffered tooth decay after using Suboxone have filed a motion to consolidate their claims into multidistrict litigation (MDL).

Multidistrict Litigation (MDL) is a legal process that brings together similar lawsuits from across the nation into one court, making the legal process more efficient and consistent. For the Suboxone Lawsuit, this means combining individual cases about dental injuries into a single, coordinated legal action, ensuring a streamlined and effective approach to these complex claims.

MDL respects the unique aspects of each case, which is especially beneficial in the Suboxone dental injury lawsuits, as it allows for individual assessment of each claim while addressing the common issue of the drug’s impact on dental health.

Pharmaceutical manufacturer Indivior Inc. has agreed to pay $385 million to settle lawsuits in the U.S. related to its opioid addiction treatment, Suboxone.

These lawsuits were brought by drug wholesalers who claimed that Indivior unlawfully suppressed generic competition for Suboxone, bringing an end to a protracted legal battle.

This settlement follows previous agreements, including a $102.5 million settlement with U.S. states and a $30 million settlement with health plans.

The trial on the wholesalers’ claims, scheduled for October 30, has now been canceled.

The settlement is pending approval from the U.S. District Court for the Eastern District of Pennsylvania, with payment expected next month.

Suboxone, approved in 2002, had exclusive rights until 2009, but the lawsuit alleged that Indivior switched to an oral film version to maintain its monopoly as generic alternatives emerged.

In 2020, the company also settled with the U.S. government for $600 million over allegations of fraudulent promotion.

Opioid-related deaths have been a significant issue in the United States, with over 900,000 deaths since 1999, according to the CDC.

Suboxone has been embroiled in legal disputes for years, including a $300 million settlement in 2021 over allegations of false marketing that led to misuse of state Medicaid funds.

This latest settlement will be paid out over seven years, and Indivior’s overdose reversal spray, Opvee, received approval in May.

Additionally, there will be a $228 million charge in the third quarter (excluded from adjusted earnings).

Consequently, the upcoming trial scheduled for October 30 has been canceled.

CEO Mark Crossley expressed satisfaction with the settlement, stating that it concludes a long-standing antitrust matter, providing greater certainty for Indivior stakeholders.

This resolution allows the company to continue its focus on assisting patients with opioid use disorder and mental health issues worldwide.

Indivior has agreed to pay $30 million to settle a class-action lawsuit filed by health plans in a U.S. court.

The lawsuit accused the drugmaker of unlawfully suppressing generic competition for its opioid addiction treatment, Suboxone.

The settlement, which still needs approval from a judge, comes after Indivior previously agreed to pay $102.5 million to settle claims by 41 U.S. states and Washington, D.C., and $600 million to resolve U.S. government allegations related to the fraudulent promotion of Suboxone.

The health plans and drug wholesalers alleged that Indivior switched to an oral film version of Suboxone to extend its monopoly, preventing generic tablet competition.

This settlement aims to resolve the legal disputes surrounding Suboxone as the opioid crisis continues to affect the United States, with more than 80,000 opioid-related overdose deaths reported in 2021.

The company that produces the opioid addiction treatment drug Suboxone, Indivior, has agreed to pay $102.5 million to settle claims with 41 U.S. states and the District of Columbia.

These states, led by Wisconsin, alleged that Indivior engaged in anticompetitive practices by making minor modifications to Suboxone to extend patent protection and prevent generic versions from entering the market.

This settlement avoids a scheduled trial.

It’s important to note that this case is distinct from claims against other opioid manufacturers related to the nationwide overdose crisis, which have resulted in settlements totaling over $50 billion.

This agreement allows Indivior to focus on its mission.

Reckitt Benckiser, the parent company, had previously agreed to pay $1.4 billion to the federal government in 2019 to resolve potential criminal and civil liability involving its Suboxone business.

Multiple attorneys general from various states were involved in this settlement.

Illinois is expected to receive approximately $2.9 million from the settlement.

As part of the settlement, Indivior is obligated to provide specific information to the states to prevent similar conduct in the future.

This includes sharing all citizen petitions submitted to the U.S. Food and Drug Administration (FDA), notifying the states about new products they plan to launch, and informing them of any proposed mergers or acquisitions.

Additionally, in 2021, Attorney General Raoul and a coalition of state attorneys general reached a $300 million national settlement with Indivior to resolve a separate lawsuit.

The lawsuit, which began in 2016, alleged that Indivior switched from a tablet version of Suboxone to an oral film version to extend its monopoly, preventing generic manufacturers from offering lower-cost tablets.

The settlement, which includes additional disclosures to prevent anticompetitive practices, awaits approval from a federal judge in Philadelphia, who oversees nationwide antitrust litigation related to Suboxone.

Indivior plans to pay the settlement in cash this month, having set aside $290 million last year for potential litigation costs.

The U.S. Food and Drug Administration (FDA) has issued a warning regarding dental problems associated with medications containing buprenorphine that are dissolved in the mouth.

These dental issues include tooth decay, cavities, oral infections, and tooth loss, even in patients with no prior history of dental problems.

Buprenorphine is an important treatment option for opioid use disorder (OUD) and pain management, and its benefits outweigh the risks.

Buprenorphine is effective in reducing withdrawal symptoms and cravings associated with opioid misuse and is often used in medication-assisted treatment (MAT) combined with counseling and behavioral therapies.

The FDA has identified 305 cases of dental problems related to buprenorphine medications dissolved in the mouth, with 131 classified as serious.

These cases span a wide age range, from 18 to 42 years and beyond.

Most cases occurred in patients using buprenorphine for OUD treatment, but 28 cases were related to pain management.

Alarmingly, 26 cases involved patients with no prior dental issues.

Some patients reported dental problems within two weeks of starting treatment, while the median time to diagnosis was approximately two years after treatment initiation.

Dental adverse events often required extensive treatment, including tooth extraction, root canals, dental surgery, crowns, and implants.

The FDA emphasizes the importance of considering the risks and benefits of buprenorphine treatment, particularly its role in MAT for OUD.